Trial Profile
A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Isavuconazole (Primary)
- Indications Aspergillosis; Candidiasis; Zygomycosis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 07 Mar 2017 Results assessing the effect of renal impairment and end-stage renal disease (ESRD) on the pharmacokinetics of isavuconazole and the inactive cleavage product (BAL8728) published in the European Journal of Clinical Pharmacology.
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 26 Sep 2014 New trial record